Norway · Delayed Price · Currency is NOK General Oceans ASA Statistics
Total Valuation
OSL:GENO has a market cap or net worth of NOK 4.18 billion. The enterprise value is 3.73 billion.
| Market Cap | 4.18B |
| Enterprise Value | 3.73B |
Important Dates
The last earnings date was Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OSL:GENO has 190.11 million shares outstanding. The number of shares has increased by 17.97% in one year.
| Current Share Class | 190.11M |
| Shares Outstanding | 190.11M |
| Shares Change (YoY) | +17.97% |
| Shares Change (QoQ) | +14.97% |
| Owned by Insiders (%) | 43.88% |
| Owned by Institutions (%) | 14.17% |
| Float | 42.86M |
Valuation Ratios
The trailing PE ratio is 20.21 and the forward PE ratio is 20.28.
| PE Ratio | 20.21 |
| Forward PE | 20.28 |
| PS Ratio | 3.14 |
| PB Ratio | 3.22 |
| P/TBV Ratio | 4.88 |
| P/FCF Ratio | 2,777.20 |
| P/OCF Ratio | 93.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.52, with an EV/FCF ratio of 2,476.67.
| EV / Earnings | 19.77 |
| EV / Sales | 2.80 |
| EV / EBITDA | 16.52 |
| EV / EBIT | 22.89 |
| EV / FCF | 2,476.67 |
Financial Position
The company has a current ratio of 2.83, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.83 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 61.90 |
| Interest Coverage | 13.59 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 22.64% |
| Return on Capital Employed (ROCE) | 11.58% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 3.58M |
| Profits Per Employee | 507,202 |
| Employee Count | 372 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OSL:GENO has paid 15.09 million in taxes.
| Income Tax | 15.09M |
| Effective Tax Rate | 7.41% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 20.53 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 56.01 |
| Average Volume (20 Days) | 161,692 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSL:GENO had revenue of NOK 1.33 billion and earned 188.68 million in profits. Earnings per share was 1.09.
| Revenue | 1.33B |
| Gross Profit | 878.32M |
| Operating Income | 162.98M |
| Pretax Income | 203.77M |
| Net Income | 188.68M |
| EBITDA | 208.01M |
| EBIT | 162.98M |
| Earnings Per Share (EPS) | 1.09 |
Balance Sheet
The company has 545.82 million in cash and 93.21 million in debt, with a net cash position of 452.60 million or 2.38 per share.
| Cash & Cash Equivalents | 545.82M |
| Total Debt | 93.21M |
| Net Cash | 452.60M |
| Net Cash Per Share | 2.38 |
| Equity (Book Value) | 1.30B |
| Book Value Per Share | 6.82 |
| Working Capital | 664.86M |
Cash Flow
In the last 12 months, operating cash flow was 44.90 million and capital expenditures -43.39 million, giving a free cash flow of 1.51 million.
| Operating Cash Flow | 44.90M |
| Capital Expenditures | -43.39M |
| Depreciation & Amortization | 45.03M |
| Net Borrowing | -146.64M |
| Free Cash Flow | 1.51M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 65.96%, with operating and profit margins of 12.24% and 14.17%.
| Gross Margin | 65.96% |
| Operating Margin | 12.24% |
| Pretax Margin | 15.30% |
| Profit Margin | 14.17% |
| EBITDA Margin | 15.62% |
| EBIT Margin | 12.24% |
| FCF Margin | 0.11% |
Dividends & Yields
This stock pays an annual dividend of 0.12, which amounts to a dividend yield of 0.59%.
| Dividend Per Share | 0.12 |
| Dividend Yield | 0.59% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.42% |
| Buyback Yield | -17.97% |
| Shareholder Yield | -17.38% |
| Earnings Yield | 4.51% |
| FCF Yield | 0.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for OSL:GENO is 28.50, which is 38.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 28.50 |
| Price Target Difference | 38.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 11.73% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OSL:GENO has an Altman Z-Score of 7.67 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.67 |
| Piotroski F-Score | 3 |